These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 1940058)

  • 1. Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients.
    De Simone C; Tzantzoglou S; Santini G; Vullo V; di Orio F; Leuter C; Jirillo E; Delia S
    Immunopharmacol Immunotoxicol; 1991; 13(3):447-58. PubMed ID: 1940058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole.
    Feola DJ; Garvy BA; Rapp RP; Thornton AC
    Pharmacotherapy; 2007 Jul; 27(7):937-47. PubMed ID: 17594199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.
    Sartori MT; Mares M; Zerbinati P; Stocco D; Girolami A
    Haematologia (Budap); 1994; 26(1):17-27. PubMed ID: 7959371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Low doses of azidothymidine in the treatment of HIV-1 virus infection].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ
    Rev Invest Clin; 1992; 44(2):161-8. PubMed ID: 1359619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
    Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
    Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV infection in the child after materno-fetal transmission: early treatment with azidothymidine and prevention of secondary infectious complications].
    Michel G; Vallée D; Thuret I; Chambost H; Tamalet C; de Boisse P; Leclaire M; Farnarier C; Kaplanski S; Perrimond H
    Pediatrie; 1992; 47(11):773-8. PubMed ID: 1364153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zidovudine therapy in combination with intravenous immunoglobulin in HIV infected children.
    Croft N; Yap PL; Mok JY; Hague RA; Burns SM
    Scott Med J; 1992 Oct; 37(5):138-41. PubMed ID: 1362818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of reduced doses of azidothymidine in Japanese patients with human immunodeficiency virus type 1 infection.
    Kimura S; Oka S; Toyoshima T; Hirabayashi Y; Kikuchi Y; Mitamura K; Shimada K
    Intern Med; 1992 Jul; 31(7):871-6. PubMed ID: 1360277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.